Conniot et al developed a novel dendritic cell-targeted mannosylated nanovaccine for melanoma, the most aggressive type of skin cancer. The study showed that the use of nanovaccine with immunotherapy could potentiate the efficacy of melanoma therapy. Researchers used anti-PD-1 antibody (αPD-1) for immunosuppression blockade and an anti-OX40 antibody (αOX40) for effector T-cell stimulation, expansion and survival. Combining the double therapy with ibrutinib, a myeloid-derived suppressor cell inhibitor, lead to a remarkable tumour remission and prolonged survival in melanoma-bearing mice. The synergy between the mannosylated nanovaccines, ibrutinib and αPD-1/αOX40 thus provided essential insights to devise alternative regimens to improve the efficacy of immune checkpoint modulators in solid tumours by regulating the endogenous immune response.
Source: Nature Nanotechnology 05 August 2019 https://www.nature.com/articles/s41565-019-0512-0